Cytokinetics (NASDAQ:CYTK) and Actinium Pharmaceuticals (NYSE:ATNM) Head to Head Analysis

Cytokinetics (NASDAQ:CYTK) and Actinium Pharmaceuticals (NYSE:ATNM) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares Cytokinetics and Actinium Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04 million	88.84	-$784.96 million	($7.22)	-8.71
Actinium Pharmaceuticals	$35.09 million	1.20	-$48.82 million	$0.36	3.71

Actinium Pharmaceuticals has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cytokinetics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Cytokinetics and Actinium Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1	1	19	0	2.86
Actinium Pharmaceuticals	0	0	1	0	3.00

Cytokinetics presently has a consensus target price of $105.44, suggesting a potential upside of 67.74%. Actinium Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 274.81%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Cytokinetics.

Insider and Institutional Ownership

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Cytokinetics and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Summary

Actinium Pharmaceuticals beats Cytokinetics on 8 of the 14 factors compared between the two stocks.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.